Seroatlas · Human Serome Atlas

PRAMEF9

PRAME family member 9

Also known as: PRAM9_HUMAN, PRAMEF15

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P0DUQ2
Gene: PRAMEF9
Ensembl: ENSG00000204501
Chromosome: 1
Canonical length: 478 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Enables ubiquitin-like ligase-substrate adaptor activity. Involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Is active in Cul2-RING ubiquitin ligase complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

478 residues, UniProt reviewed canonical sequence.

>P0DUQ2|PRAMEF9
     1  MKMSIRTPPR LLELAGRSLL RDQALAMSTL EELPTELFPP LFMEAFSRRR CEALKLMVQA
    61  WPFRRLPLRP LIKMPCLEAF QAVLDGLDAL LTQGVRPRRW KLQVLDLQDV CENFWMVWSE
   121  AMAHGCFLNA KRNKKPVQDC PRMRGRQPLT VFVELWLKNR TLDEYLTYLL LWVKQRKDLL
   181  HLCCKKLKIL GMPFRNIRSI LKMVNLDCIQ EVEVNCKWVL PILTQFTPYL GHMRNLQKLV
   241  LSHMDVSRYV SPEQKKEIVT QFTTQFLKLR CLQKLYMNSV SFLEGHLDQL LSCLKTSLKV
   301  LTITNCVLLE SDLKHLSQCP SISQLKTLDL SGIRLTNYSL VPLQILLEKV AATLEYLDLD
   361  DCGIIDSQVN AILPALSRCF ELNTFSFCGN PICMATLENL LSHTIILKNL CVELYPAPRE
   421  SYGADGTLCW SRFAQIRAEL MNRVRDLRHP KRILFCTDYC PDCGNRSFYD LEADQYCC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAMEF9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.27
Highest tissue expression: 0.1 nTPM

Expression across tissuesHPA

Tissue

liver: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM

Single-cell type

transitional alveolar cells: 0.1 nCPM
adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.84
gnomAD pLI: 0.33

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ubiquitin-like ligase-substrate adaptor activity

Cellular components

Cul2-RING ubiquitin ligase complex

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAMEF9 as an antibody target. Whether an autoantibody or antibody against PRAMEF9 could matter depends on whether native PRAMEF9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAMEF9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRAMEF9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...